Characteristics All Responders Non-responders p- value
Demography Demography Demography Demography Demography
Sex (females, %) 14/21 (66.7%) 6/10 (60%) 4/11 (36.4%) NS
Age (yrs., ± SD) 46.3 (9.7) 39.1 (8.10) 51.36 (8.13) 0.003
Disease duration (yrs., ± SD) 9.1 (7.49) 7.4 (8.13) 10.8 (6.78) NS
Disease Characteristics Disease Characteristics Disease Characteristics Disease Characteristics Disease Characteristics
Non-infectious complications (no. of pts., %) 16/21 (76.2%) 7/10 (70%) 9/11 (81.8%) NS
Baseline immunosuppression (no. of pts., %) 3/21 (14.3%) 1/10 (10%) 2/11 (18.2%) NS
Previous immunosuppression (no. of pts., %) 2/21 (9.5%) 0/10 (0%) 2/11 (18.2%) NS
Treatment Characteristics Treatment Characteristics Treatment Characteristics Treatment Characteristics Treatment Characteristics
IRT dose (mg/kg/month, ± SD) 288 (69.6) 262 (60.52) 310.9 (71.62) NS
Serum IgG (trough g/L, ± SD) 6.13 (1.59) 6.28 (1.94) 6.0 (1.27) NS
ATB prophylaxis (no. of pts., %) 3/21 (14.3%) 1/10 (10%) 2/11 (18.2%) NS
Laboratory Parameters Laboratory Parameters Laboratory Parameters Laboratory Parameters Laboratory Parameters
Serum IgA (g/L, ± SD) 0.1 (0.09) 0.13 (0.13) 0.08 (0.03) NS
Serum IgM (g/L, ± SD) 0.19 (0.18) 0.29 (0.21) 0.1 (0.06) 0.002
Lymphocytes (E9/L, ± SD) 1.49 (0.7) 1.52 (0.52) 1.42 (0.85) NS
CD4+ (% of CD3+ cells, ± SD) 57.69 (7.38) 59.20 (5.36) 56.75 (8.62) NS
CD4+ naїve (% of CD4+ cells, ± SD) 15.51 (13.3) 22.44 (16.24) 11.18 (9.89) NS
CD4+ TREG (% of CD4+ cells, ± SD) 12.27 (5.54) 15.04 (6.28) 10.54 (4.6) NS
CD8+ (% of CD3+ cells, ± SD) 38.46 (8.17) 36.40 (6.07) 39.75 (9.41) NS
CD8+ naїve (% of CD8+ cells, ± SD) 23.47 (9.58) 26.0 (7.42) 21.89 (10.88) NS
CD8+ senescent (% of CD8+ cells, ± SD) 49.23 (16.44) 41.0 (18.75) 54.38 (13.56) NS
CD19+ (% of lymphocytes, ± SD) 11.19 (6.79) 8.52 (3.06) 12.86 (8.09) NS
CD19+ transitional (% of CD19 cells, ± SD) 7.48 (15.94) 2.34 (1.42) 10.7 (20.10) NS
CD19+ naїve (% of CD19+ cells, ± SD) 68.46 (22.86) 56.0 (18.41) 76.25 (22.84) NS
CD19+ CS (% of CD19+ cells, ± SD) 5.0 (3.2) 7.58 (3.09) 3.39 (2.09) 0.009
CD19+ CD21low (% of CD19 cells, ± SD) 15.0 (21.16) 11.64 (6.99) 17.1 (26.96) NS
T-Cell Response T-Cell Response T-Cell Response T-Cell Response T-Cell Response
Cellular response at month 1 (no. of pts., %) 5/13 (38.5%) 3/8 (37.5%) 2/5 (40%) NS
Cellular response at month 6 (no. of pts., %) 8/12 (66.7%) 5/7 (80%) 3/5 (60%) NS